Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on February 18, 2021, covering events occurring on February 16 and 17, 2021. The filing details a material definitive agreement involving a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock.
- Shares Issued: 1,321,132 shares of Common Stock ($0.0001 par value).
- Purchase Price: $7.75 per share.
- Gross Proceeds: $10,238,773.
- Net Proceeds: Anticipated $9,830,610 (after deducting placement agent fees and expenses).
- Use of Proceeds: General corporate purposes.
- Expected Closing Date: On or about February 23, 2021.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with several accredited investors. Key terms include:
- Placement Agent: Tribal Capital Markets, LLC was engaged for a cash fee of 3% of gross proceeds and warrants to purchase up to 79,268 shares at an exercise price of $9.30 for a two-year period.
- Financial Advisor: Allele Capital Partners, LLC was engaged for a fee of $10,000 per month for six months.
- Registration Rights: The Company agreed to file a Resale Registration Statement with the SEC within 30 days of filing (or 75 days if reviewed). Failure to meet these deadlines may trigger liquidated damages payable to purchasers.
- Exemptions: The offering is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance, revenue projections, or management commentary regarding future operational performance. The primary risks and contingencies identified are:
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Registration Deadlines: The Company faces potential liquidated damages if it fails to declare the Resale Registration Statement effective within the specified timeframes.
- Representations: The filing explicitly states that representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as statements of fact regarding the Company's actual condition.
Investor Verification Checklist
- Verify the actual closing date of the offering and confirmation of net cash proceeds received.
- Monitor the filing and effectiveness status of the Resale Registration Statement to assess potential liquidated damages exposure.
- Review the specific terms of the warrants issued to Tribal Capital Markets, LLC (Exhibit 10.3).
- Confirm the allocation of the $9.8 million in net proceeds as "general corporate purposes" is executed as intended.